Company Overview
Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS). The company offers Platinum and Platinum Pro NGPS instruments for single-molecule, amino acid level resolution, and automated data analysis; library preparation kits to prepare a customer's protein sample for sequencing; and sequencing kits, which contain the reagents and consumables used to perform NGPS. It also provides Platinum analysis software, a cloud-based solution that automates data analysis workflows and visualizes the sequencing results. The company was founded in 2013 and is headquartered in Branford, Connecticut.
Recent Developments
- Dec 2025 Revenue of $2.44M (-20.3% YoY); net profit $-101.34M.
- Trailing 12 Months Year-on-year growth — revenue -69.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -69.40% |
Stock Price Performance
| 1 Year: | -49.94% |
| 6 Months: | -29.02% |
| 3 Months: | +9.76% |
| 1 Month: | -11.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.49 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 67.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | QSI Quantum-Si incorporated R2K | 0.87 | -1.74 | $172.11M | 0.00% | -52.16% | -46.38% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 0 | 0 | 0 | 254.00K | 205.00K | 223.00K | 457.00K | 622.00K | 787.00K | 842.00K | 591.00K | 552.00K | 258.00K |
| Gross Profit | - | - | - | - | - | - | 0 | 0 | 0 | 124.00K | 78.00K | 108.00K | 269.00K | 354.00K | 367.00K | 486.00K | 351.00K | 194.00K | 74.00K |
| Operating Income | - | -8.20M | -8.55M | -11.78M | -32.16M | -25.18M | -27.14M | -30.20M | -27.66M | -29.22M | -26.89M | -27.18M | -23.36M | -26.45M | -28.09M | -25.11M | -30.12M | -39.77M | -24.05M |
| Net Income | -10.31M | -8.20M | -8.56M | -11.78M | -35.70M | -18.09M | -35.17M | -32.41M | -31.71M | -23.61M | -25.57M | -24.73M | -19.47M | -23.10M | -25.31M | -19.19M | -28.84M | -35.70M | -21.67M |
| Diluted EPS | - | -1.53 | -1.60 | -2.13 | -0.97 | -0.13 | -0.25 | -0.23 | -0.23 | -0.17 | -0.18 | -0.17 | -0.14 | -0.16 | -0.18 | -0.11 | -0.16 | -0.17 | -0.10 |
| R&D Expense | - | 6.59M | 6.66M | 7.97M | 13.11M | 11.10M | 18.77M | 18.46M | 16.68M | 18.17M | 15.83M | 16.59M | 12.10M | 14.38M | 16.17M | 13.72M | 15.21M | 13.88M | 14.49M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 1.08M | 3.06M | 2.44M |
| Gross Profit | - | - | 0 | 0 | 488.00K | 1.60M | 1.15M |
| Operating Income | -36.62M | -36.69M | -96.91M | -123.84M | -111.17M | -108.58M | -116.10M |
| Net Income | -35.79M | -36.61M | -94.99M | -132.44M | -95.96M | -101.01M | -101.34M |
| Diluted EPS | -6.95 | -6.84 | -1.19 | -0.95 | -0.68 | -0.71 | -0.51 |
| R&D Expense | 28.10M | 27.55M | 46.58M | 72.06M | 67.03M | 59.64M | 53.76M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Jun 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 40.59M | 503.23M | 391.49M | 298.25M | 247.87M | 245.61M |
| Total Equity | -92.14M | -125.10M | 0 | -159.72M | 477.03M | 358.71M | 271.62M | 215.42M | 220.23M |
| Cash & Equivalents | - | - | - | 36.91M | 35.78M | 84.32M | 133.86M | 49.24M | 21.64M |
| Total Liabilities | - | - | - | 4.50M | 26.19M | 32.78M | 26.63M | 32.45M | 25.38M |
| Current Liabilities | - | - | - | 2.75M | 11.53M | 15.71M | 11.61M | 18.19M | 23.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -30.71M | -32.57M | -66.81M | -90.56M | -94.04M | -87.80M | -94.72M |
| Investing Cash Flow | -1.24M | -461.00K | -450.94M | 137.19M | 143.43M | -32.67M | -28.32M |
| Financing Cash Flow | 18.22M | 37.01M | 516.62M | 1.91M | 149.00K | 35.88M | 95.42M |
| Capital Expenditure | -1.24M | -461.00K | -5.76M | -10.74M | -4.51M | -4.58M | -2.52M |
| Free Cash Flow | -31.95M | -33.03M | -72.58M | -101.30M | -98.55M | -92.38M | -97.23M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 45.1% | 52.3% | 47.3% |
| Operating Margin % | - | - | - | - | -10,274.6% | -3,550.6% | -4,766.0% |
| Net Margin % | - | - | - | - | -8,868.8% | -3,303.0% | -4,160.1% |
| ROE % | 28.6% | 22.9% | -19.9% | -36.9% | -35.3% | -46.9% | -46.0% |
| ROCE % | - | -97.0% | -19.7% | -33.0% | -38.8% | -47.3% | -52.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for QSI
Is Quantum-Si (NASDAQ:QSI) In A Good Position To Invest In Growth? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOOUU1UDYzZHUzd1E1dU1DVzlTMDV2QS1Oa3lncW56MjlZZ0hNbUhJbjlpSmMzSWp0ZGNCX0RpMURVS0dRZV9PTEsteUhyZEdaZGlfbTFRdk9XRndzQ3BRUkwwYkVQa25CaVlCVl9XUlRtLTJSSG9KOUJYTFRsbDRaaWFGYzFIN1dQOVN2MH…
QSI Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE9PYUpUY0J5Y2J0c2RKZ25yWEtNaEdxMGE1Qjc5SmpIdjRQdXgtelhGZnVYMy1nd2NFU0s2dW5iTUJNTVhTbnpZSnFzREI1NXRZYTh3SXVEVWVtSVVvMzhWdHYxNjF0ckxVaEhWMzhBWEVBVWZSUnp0Zg?oc=5" target="_blank">QSI F…
Quantum-Si (QSI) CEO Jeffrey Hawkins reports $20,996 stock sale - Investing.com
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOMmxHTmZWS3c0bDQ3cDN4OEdON0x2R2UtYlAzMGNEVjYzYWsycGpJbGxxVTBXeFhPOUdERTRUSEFuelN5WGR3RlVMaEFxbXFab3ltUGQ1U0dfU0tEVWhqSkx0aUhUd0dPemIwVzhrX3laOGp2azFfWU52V3ZWSDJDU0xXRXZzYk5vcFdtX0…
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQYlV1cmh4eTlmckl3ZlI5WFlqNXlQZ2tPTm9ubUVPZUVjQmJfdWV2ZFdrM3dxdkdfN09DSU03VkwzcUNSZkFJc1NHczZxRTYxRVdRZWJ0RTFIdnJ0M19rVURNSU1QaHhRZkk4OUFIaWNfTnA5THNKaVNjYVpNdWUydnpvd3dQT2Naa3BmNW…
Insider Sale: Chief Financial Officer of $QSI Sells 4,116 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQSzlHT1dLOERkRkUxenJWbm1XalU0RTN2ODRra3p2SVpTS3BmbHFRbjNrNjlrSHdmN1o1cDJReUpmU2tPRlRJMmxuOGVFWkhobUZ1MTdrRDc3NXZ1Y2NHZzdaTjBVeHVjeXFRMXYyUkdXTVBSSG1abThQeXNDcDU0V3hRNWtpSGlLdE1yNC…
QSI Stock Grinds Higher As Proteus Milestones Pile Up - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxNcUxta2VRQWZQQ3hVT1RfMk9yMGF5N2hGdXZCZ19OXzE5RFZIWHQ5TERDYUNwY092UDJPMXg1dzNmd0xwUE1oSTkta2Y5S09VdmNXUHkxZnV6TThFMjhiMmtxNzFVVFJOQlNEUUVHdUk4WlF3dWRzb0Z0b3FiVXM5Rg?oc=5" target="_…
QSI — Frequently Asked Questions
What is the current share price of Quantum-Si incorporated (QSI)?
As of 2026-07-14 21:23 PDT, Quantum-Si incorporated (QSI) trades at $0.87 on NasdaqGM. Its 52-week range is $0.71 to $2.63.
What is the market capitalisation of QSI?
Quantum-Si incorporated (QSI) has a market capitalisation of $172.11M on NasdaqGM.
What is the P/E ratio of QSI?
QSI trades at a trailing price-to-earnings (P/E) ratio of -1.74. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.02.
What is the return on equity (ROE) of QSI?
QSI has a return on equity (ROE) of -46.38%. Its return on capital employed (ROCE) is -52.16%.
Is QSI a good stock to buy?
This page provides a data-driven analysis of Quantum-Si incorporated (QSI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.